TRAIL receptor mediates inflammatory cytokine release in an NF-B-dependent manner

Cell Research

Volumn 19, Issue 6, 2009, Pages 758-767

  Tang, Wanhu ^a   Wang, Weimin ^a   Zhang, Yaxi ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Cytokine; Inflammation; NF ?B; TRAIL receptor

Indexed keywords

CCL4 PROTEIN, HUMAN; CXCL2 CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL LINE; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE; CHEMOKINE CCL20; CHEMOKINE CCL4; CHEMOKINE CXCL2; CYTOKINES; HUMANS; INTERLEUKIN-8; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649982926     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.57     Document Type: Article

References (34)

1. Walczak H, Miller RE, Ariail K, et a.. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in viv.. Nat Me. 1999; 5:157-163.
2. Ashkenazi A, Pai RC, Fong S, et a.. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Inves. 1999; 104:155-162.
3. Pan G, O'Rourke K, Chinnaiyan AM, et a.. The receptor for the cytotoxic ligand TRAIL. Scienc. 1997; 276:111-113.
4. Walczak H, Degli-Esposti MA, Johnson RS, et a.. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. EMBO. 1997; 16:5386-5397.
5. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunit. 1997; 7:821-830.
6. Sprick MR, Weigand MA, Rieser E, et a.. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunit. 2000; 12:599-609.
7. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunit. 2000; 12:611-620.
8. Bodmer JL, Holler N, Reynard S, et a.. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Bio. 2000; 2:241-243.
9. Anel A, Bosque A, Naval J, et a.. Apo2L/TRAIL and immune regulation. Front Biosc. 2007; 12:2074-2084.
10. Grosse-Wilde A, Voloshanenko O, Bailey SL, et a.. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Inves. 2008; 118:100-110.
11. Zerafa N, Westwood JA, Cretney E, et a.. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immuno. 2005; 175:5586-5590.
12. Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ. Normal thymocyte negative selection in TRAILdeficient mice. J Exp Me. 2003; 198:491-496.
13. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immuno. 2003; 4:255-260.
14. Janssen EM, Droin NM, Lemmens EE, et a.. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Natur. 2005; 434:88-93.
15. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immuno. 2003; 171:1526-1533.
16. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Bloo. 2005; 105:3413-3419.
17. Secchiero P, Gonelli A, Carnevale E, et a.. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulatio. 2003; 107:2250-2256.
18. Zauli G, Pandolfi A, Gonelli A, et a.. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Re. 2003; 92:732-740.
19. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J Biol Che. 2001; 276:34743- 34752.
20. Varfolomeev E, Maecker H, Sharp D, et a.. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Che. 2005; 280:40599-40608.
21. Choi C, Kutsch O, Park J, Zhou T, Seol DW, Benveniste EN. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Bio. 2002; 22:724- 736.
22. Guo Y, Chen C, Zheng Y, et a.. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Che. 2005; 280:41940-41952.
23. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Bio. 1995; 5:392-399.
24. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Scienc. 1998; 281:1680-1683.
25. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes De. 1999; 13:382-387.
26. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Bio. 1999; 19:5923-5929.
27. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bclx( L). Mol Cell Bio. 2000; 20:2687-2695.
28. Mitsiades CS, Treon SP, Mitsiades N, et a.. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Bloo. 2001; 98:795-804.
29. Trauzold A, Wermann H, Arlt A, et a.. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogen. 2001; 20:4258-4269.
30. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogen. 2001; 20:3888-3896.
31. Wuchter C, Krappmann D, Cai Z, et a.. In vitr. susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemi. 2001; 15:921-928.
32. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogen. 2007; 26:3364-3377.
33. Weckmann M, Collison A, Simpson JL, et a.. Critical link between TRAIL and CCL20 for the activation of T(H)2 cells and the expression of allergic airway disease. Nat Me. 2007; 13:1308-1315.
34. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Let. 1998; 424:41-45.